What the FDA labels say about taking them together
Berahyaluronidase alfa/pembrolizumab and hyaluronidase
Berahyaluronidase alfa/pembrolizumab's FDA label of July 31, 2026 names hyaluronidase in its contraindications section; the hyaluronidase labels PlainMeds reads (2) do not name berahyaluronidase alfa/pembrolizumab. The berahyaluronidase alfa/pembrolizumab label: “CONTRAINDICATIONS KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to berahyaluronidase alfa, hyaluronidase or to any of its excipients.”
Check it at the source: the berahyaluronidase alfa/pembrolizumab FDA label on DailyMed (effective July 31, 2026); the hyaluronidase FDA label on DailyMed (effective February 1, 2024, Amphastar Pharmaceuticals, Inc.).
What does the berahyaluronidase alfa/pembrolizumab label say about hyaluronidase?
Berahyaluronidase alfa/pembrolizumab label, contraindicationsCONTRAINDICATIONS KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to berahyaluronidase alfa, hyaluronidase or to any of its excipients.
Source: FDA drug label (KEYTRUDA QLEX), Merck Sharp & Dohme LLC, effective July 31, 2026 (SPL set 097d166f-b73b-41d3-9b37-7653cd2a0c41), via openFDA; the full label on DailyMed
What does the hyaluronidase label say about berahyaluronidase alfa/pembrolizumab?
Hyaluronidase's label (effective February 1, 2024) and its 1 other brand-application label do not name berahyaluronidase alfa/pembrolizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (AMPHADASE), Amphastar Pharmaceuticals, Inc., effective February 1, 2024 (SPL set 8396ea96-7cb5-4e26-87a4-90bca9c3c6dd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Berahyaluronidase alfa/pembrolizumab | Hyaluronidase | |
|---|---|---|
| Labeled for | Lung cancer, Colorectal cancer, Breast cancer | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $53.69 per mL 150 units/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once